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Abstract
Background: As the population ages, peripheral arterial disease (PAD) in the lower extremities
will become a larger public health problem. Awareness in patients as well clinicians of the high risk
of morbidity and mortality is important but seems currently low. Insights in absolute mortality risks
following admission for PAD in the lower extremities can be useful to improve awareness as they
are easy to interpret.
Methods: A nationwide cohort of 4,158 patients with an initial admission for PAD in the lower
extremities was identified through linkage of the national hospital and population register in 1997
and 2000.
Results: Over 60% of 4,158 patients were men. 28 days, 1 year and 5 year mortality risk were
2.4%, 10.3% and 31.0% for men and 3.5%, 10.4% and 27.4% for women. Coronary heart disease and
stroke were frequent cause of death. Five years mortality risk was higher for men compared to
women (HR 1.36, 95% CI 1.21–1.53).
Conclusion: In conclusion, our findings demonstrate that, 5 year mortality risk is high, especially
in men and comparable to that of patients admitted for acute myocardial infarction or ischemic
stroke. Though, in general population the awareness of the severity of PAD in the lower
extremities is significantly lower than that for any other cardiovascular disease and it seems that
cardiovascular risk factor management for prevention in PAD patients is very modest.
Background
Peripheral arterial disease (PAD) is a manifestation of
atherosclerosis, affecting an estimated 27 million people
in Europe and North America [1]. Intermittent claudica-
tion (IC) is the most common symptom of PAD in the
lower extremities. IC has a severe impact on various
aspects of quality of life [2,3], on the ability to continue to
work and approximately 15% to 20% of the patients with
IC develop critical limb ischemia (CLI) [4,5]. Further-
more, patient with IC have an increased mortality risk
compared to the general population [6,7].
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Previous studies reported that individuals with PAD have
a 20–60% increased risk for myocardial infarction, a two-
to six-fold increased risk of cardiovascular death, and a
40% increased risk of stroke compared to those without
PAD [5,8,9]. In spite of many publications reporting an
increased risk of morbidity and mortality, patients with
PAD lack knowledge regarding the risk of heart attack,
stroke and total mortality [10]. Furthermore, the use of
secondary prevention treatment in these patients have
shown to be modest at best [11].
Although PAD in the lower extremities is rare among
young individuals its prevalence increases dramatically
with age [7,12]. As the population ages, PAD in the lower
extremities will become a greater public health problem
[7,12], leading to an increasing necessity for primary and
secondary prevention. Awareness in patients as well clini-
cians of the high risk of morbidity and mortality is there-
fore important. Most available literature, including
institutional and population-based studies, present over-
all mortality risks for patients with PAD in the lower
extremities [13-17] or use relative risks or odds ratio's
when reporting mortality [8,11,16]. However, absolute
mortality risks stratified by age and gender may be more
useful as absolute risks are easier to interpret and they pro-
vide a clearer presentation of the size of the burden of dis-
ease in these patients. We set out to study absolute
mortality risk stratified by age and gender after first hospi-
tal admission for PAD in the lower extremities.
Methods
Registries and linkage procedure
To construct a cohort of patients admitted for the first
time because of PAD in the lower extremities, information
from the national Hospital Discharge Registry (HDR) and
the Dutch Population Registry (PR) were linked. Informa-
tion on cause of death was derived from the cause of death
registry of Statistics Netherlands. The registries and link-
age procedures have been described in detail previously
for a cohort of acute myocardial infarction patients [18]
and stroke [19]. In brief, the HDR is a nationwide data-
base on admissions, not persons. For each hospital admis-
sion a new record is created in the HDR. Following
individuals over time based on HDR-information alone is
troublesome due to difficulties in identification of differ-
ent admissions from the same person in time and admis-
sions for the same condition at a different hospital (due to
referral or to address changes). Yet, linkage (linkage varia-
bles date of birth, gender and 4 digits of postal code) with
the PR may overcome these issues.
For the present study, cohorts were extracted from 1997
and 2000 because of pragmatic reasons at the time of the
initiation of the project in 2001. The total population of
the Netherlands in 1997 and 2000 was 15,567,107 (men
7,696,803, women 7,870,304) and 15,863,950 (men:
7,846,317, women: 8,017, 633), respectively.
Definition
PAD in the lower extremities was defined using the Inter-
national Classification of Diseases, 9th Revision [20] code
4439. This code is described as peripheral vascular disease
unspecified, intermittent claudication not otherwise spec-
ified (NOS). Peripheral: angiopathy NOS, vascular disease
NOS, Spasm of artery. Excluded are atherosclerosis of the
arteries of the extremities and spasm of cerebral artery.
The ICD code does not provide information on severity.
We assume that patients with moderate-severe claudica-
tion, ischemic rest pain and ulceration or gangrene (Fon-
taine stage IIb, III and IV, respectively) are hospitalized as
these patients have an indication for surgical interven-
tions [3]
Study population
All hospital admissions for PAD in the lower extremities
between January 1st and December 31st, 1997 and January
1st  and December 31st, 2000, were selected from the
national hospital discharge registry (which was previously
linked with PR). There were 7,161 hospital admissions.
Selection of the first admission for an individual of all
subsequent admissions of a person occurring 1997 and
2000 yielded a total of 5,886 patients with PAD in the
lower extremities. Subsequently, information was col-
lected on hospital admission that may have occurred pre-
viously (1995–1997(data earlier than 1995 not available
since linkage with PR is only possible from 1995) and
1995–2000, respectively) for the same condition. Those
with a previous admission for peripheral arterial disease
were excluded (n = 1,728). This resulted in a cohort con-
sisting of 4,158 patients with a first hospitalization for
PAD in the lower extremities in 1997 or 2000 in the Neth-
erlands.
Co-morbidity
The presence of co-morbidity (cardiovascular disease
(ICD-9-CM codes 390–459) or diabetes mellitus (DM)
(ICD-9-CM code 250)) was determined on the basis of
the discharge diagnosis of previous hospital admissions
or on the basis of a secondary diagnosis at the time of the
index admission. No information in the registry was avail-
able on the severity of disease, risk factor (hypertension,
smoking) or medication use.
Follow-up
Information on mortality was obtained by linkage of the
cohort with national cause of death register. Linkage of
the PR (which was linked previously to the HDR cohort)
with the cause of death register was performed using an
unique identification key and therefore was nearly com-BMC Cardiovascular Disorders 2009, 9:43 http://www.biomedcentral.com/1471-2261/9/43
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plete. Patients were censored if they migrated out of the
Netherlands or if their linkage key was not unique any-
more during follow-up. Causes of death were coded using
the tenth revision of the International Classification of
Disease (ICD-10) [21].
Data analysis
Survival time was calculated as the time from the initial
admission date for IC in 1997 or 2000 to the date of death
from any cause or to the date that a patient was censored,
whichever came first. The crude short-term (28 day), 1
year and long-term (5-year) mortality were computed by
age and gender according to the actuarial life table
method and expressed as percentages. The mortality rate
in men was compared to mortality rate in women by cal-
culating relative risks (with 95% CI). Cox regression mod-
els were used to study differences between men and
women in their risk of death. Mortality at 28-days, 1-year
and 5-years was examined. For each period, a model was
fitted to adjust for for age and co-morbidity (previous
admissions for cardiovascular disease or DM). Data were
analyzed with SPSS software, version 14.0 (SPSS Inc, Chi-
cago, Illinois, USA). All analyzes were performed in agree-
ment with privacy legislation in the Netherlands [22].
Results
A total of 4,158 patients with a first hospital admission for
a PAD in the lower extremities in 1997 or 2000 were iden-
tified. General characteristics are provided in Table 1. Two
percent, 10% and 31% of all men and 4%, 10% and 27%
of all women died within 28 days, 1-year and 5-years,
respectively.
Cause of death
Cardiovascular diseases were the most frequent cause of
death at 28-days, 1-year and 5-years (Table 2). The contri-
bution of cardiovascular diseases as cause of death
decreased over time while the contribution of cancer as a
cause of death increased.
28-day mortality
Short term mortality risk increased with age in men and
women (from 2.3% in men between 65–69 years to
18.4% in men older than 85 years and from 2.3% in
women between 50–54 years to 18.8% in women older
than 85 years) (Table 3). The crude overall mortality was
lower for men (relative risk 0.67; 95% CI 0.47 to 0.96).
After adjustment for potential confounding factors no dif-
ferences between men and women in mortality were
observed (Table 4).
One-year mortality
Mortality increased with age in men and women (from
1.8% in men younger than 45 years to 47.7% in men
older than 85 years and from 3.9% in women between
50–54 years to 41.0% in women older than 85 years). A
higher mortality in men compared with women was
found across all ages above 55 years, however differences
Table 1: Characteristics of patients with a first hospitalization for PAD in the lower extremities in 1997 or 2000.
Men Women Total
Number of patients 2,539 1,619 4,158
Age at admission (years)
Mean 66.1 66.9 66.4
Standard deviation 11.6 13.9 12.6
Previous hospital admission in 1995–1997, 1995–2000 (%)
cardiovascular disease 28.9* 25.0 27.3
- ischemic heart disease 13.6* 8.6 11.7
- acute myocardial infarction 3.7 3.2 3.5
- congestive heart failure 3.9 3.5 3.8
- stroke 4.6* 3.3 4.1
- other cardiovascular disease 14.0 15.2 14.5
diabetes mellitus 10.8 13.3* 11.8
Type of hospital (%)
- academic 11.2* 7.8 9.9
Length of stay (days)
Mean 454
Origin (%)
-native 91.5 89.5 90.7BMC Cardiovascular Disorders 2009, 9:43 http://www.biomedcentral.com/1471-2261/9/43
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were not statistically significant (Table 3). The mortality
risks at 1-year were similar for men and women (Table 4).
Five-year mortality
Mortality risk at 5-year was 8.3% for men younger than 45
years, 84.2% for men older than 85 years, 1.7% for
women younger than 45 years and 74.4% for women
older than 85 year (Table 4). The crude overall mortality
was higher for men (relative risk 1.31;95% CI 1.03 to
1.25) which persisted after adjustment for potential con-
founding factors (Table 4).
Discussion
This study provides estimates of absolute short- and long-
term risk of death after an initial hospital admission for
PAD in the lower extremities. Our findings demonstrate
that, although short-term mortality risk after initial
admission for PAD in the lower extremities is relatively
low, 5-year mortality risk is high, especially in men.
One-year mortality rates were higher in the present study
than those reported in intervention studies evaluating the
effect of drug treatment for IC [23-25]. In these trials, mor-
tality risks (around 1.2% after 1 year) were much lower
than the mortality risk in our study population (mortality
risk 10.4% after 1 year). This likely reflects exclusion of
the sickest patients from participation in trials [26]. Gen-
der stratified 1-year and 5-years mortality risks (6% and
38% in men and 4% and 20% in women, respectively)
that were reported for patients first seen with IC in hospi-
tal [5] were also somewhat lower in comparison with our
findings, except for 5-years mortality in men. Much higher
gender stratified 1-year and 5-years mortality risks (22%
and 67% in men and 17% and 62% in women, respec-
tively) have been reported for patients with CLI [27].
However, comparison between these studies and our
study is difficult, as the baseline clinical characteristics of
the patients in the present study are mostly unknown.
Whereas studies reporting stratified (for age and/or gen-
der) mortality risks for patients with PAD in lower extrem-
ities are scarce, many studies reported mortality risks for
PAD patients stratified by ankle-brachial index (ABI)
[14,16,28]. These studies indicate that a low ABI is associ-
ated with high mortality risk. Five-year mortality risks of
16% and 34% have been reported for patients with ABI
0.71–0.9 and <0.7, respectively [15] and 34% and 56%
for patients with ABI 0.4–0.85 and ABI <0.4 [28]. The get-
ABI study [29] reported higher risk of death in patients
with peripheral disease (low ABI) compared with those
without (hazard ratio 2.3), suggesting that ABI may be a
good risk predictor beyond conventional risk predictors
[30].
The long-term risk of death of patients with a first hospi-
talization for PAD in the lower extremities is high com-
pared to risk of death in the general population (Figure 1
and Figure 2). Furthermore, comparison with survival
after admission for other atherosclerotic diseases such as
acute myocardial infarction and ischemic stroke showed
similar mortality risks (Figure 1 and Figure 2) [13,18,31].
In contrast, awareness of the severity of PAD in the lower
extremities is low as in general population the familiarity
with this disease is significantly lower than that for any
other cardiovascular disease. A recent study showed that
26% of the public was familiar with the disorder and of
Table 2: Causes of death at 28-days, 1-year and 5-years of patients with a first hospitalization for PAD in the lower extremities in the 
Netherlands.
Cause of death 28 days 1-year 5-years
Men Women Men Women Men Women
(n = 60) (n = 57) (n = 262) (n = 168) (n = 786) (n = 443)
Cardiovascular diseases 70.0 68.4 55.0 61.9 50.3 53.7
- ischemic heart disease 23.3 12.3 14.5 15.5 17.4 14.7
- AMI 11.7 8.8 7.6 11.3 10.3 10.4
- congestive heart failure 5.0 7.0 5.7 6.5 4.8 4.7
- stroke 1.7 7.0 9.2 8.3 8.9 7.9
- peripheral arterial diseases 33.3 35.1 19.8 22.6 12.1 15.3
- other cardiovascular diseases 6.7 7.0 5.7 8.9 7.0 11.1
Cancer 5.0 1.8 13.7* 6.5 18.1 12.6
- lung cancer 3.3 0.0 5.7 2.4 6.9 3.8
Diseases of respiratory system 11.7 7.0 9.5 6.5 9.9 8.1
- COPD 5.0 5.3 5.0 3.6 5.2 3.8
Complications from DM 8.3 12.3 8.8 11.9 7.3 10.8
Other 5.0 10.5 13.0 13.2 14.4 14.8
* Age-adjusted gender difference significant
Values are number of deaths expressed as a percentage of total number of deaths
AMI: acute myocardial infarction, COPD: chronic obstructive respiratory disease, DM: diabetes mellitusBMC Cardiovascular Disorders 2009, 9:43 http://www.biomedcentral.com/1471-2261/9/43
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those only 14% was aware that the disease could lead to
death [32]. Furthermore, PAD patients tend to be under-
treated compared to patients with other manifestations of
atherosclerosis and it seems that cardiovascular risk factor
management for prevention in PAD patients is very mod-
est [33,34].
Strength of our study is the large size of the cohort
obtained from usual care with a large age range and infor-
mation on both men and women. Even though the valid-
ity of national registries has been questioned, several
studies have shown that for the Netherlands, the validity
is adequate [35,36]. Furthermore a high validity of the
linkage between them has been demonstrated [36,37].
We provided detailed information on age- and gender-
specific risks, while a large number of publications,
including institutional and population-based studies,
simply present overall mortality risks of groups of patients
without the presentation of the information by age and
gender, despite the evidence that mortality depends on
age and gender.
Besides age and gender, there are many other factors that
may contribute to the prognosis of PAD patients. The
stage of PAD, presence of traditional cardiovascular risk
factors (e.g. smoking) [38], physical inactivity [39], sys-
temic inflammation [40], impaired renal function [41],
hypercholesterolemia, statin use and ABI lower than 0.60
Table 3: Mortality risk at 28 days, 1 year and 5 years after a first hospital admission (1997 or 2000) for PAD in the lower extremities in 
the Netherlands, by age and gender.
Men Women RR (95% CI) for
Men vs Women
No. of men No. of women Age No. of Deaths Percentage
Deaths
No. of Deaths Percentage
Deaths
28-day mortality 109 116 < 45 - - - - -
133 95 45–49 - - - - -
236 128 50–54 - - 3 2.3 -
263 116 55–59 - - - - -
322 162 60–64 - - - - -
444 215 65–69 10 2.3 4 1.9 1.21 (0.38–3.82)
425 285 70–74 6 1.4 3 1.1 1.34 (0.34–5.32)
363 242 75–79 15 4.1 11 4.5 0.91 (0.42–1.95)
168 143 80–84 13 7.7 11 7.7 1.0 (0.47–2.18)
76 117 85+ 14 18.4 22 18.8 0.98 (0.54–1.79)
2,539 1,619 all ages 60 2.4 57 3.5
1-year mortality 109 116 < 45 2 1.8 - - -
133 95 45–49 3 2.3 - - -
236 128 50–54 7 3.0 5 3.9 0.75 (0.25–2.34)
263 116 55–59 7 2.7 3 2.6 1.03 (0.27–3.91)
322 162 60–64 22 6.8 9 5.6 1.23 (0.58–2.61)
444 215 65–69 36 8.1 14 6.5 1.25 (0.69–2.26)
425 285 70–74 50 11.8 23 8.1 1.46 (0.91–2.33)
363 242 75–79 55 15.2 31 12.8 1.18 (0.79–1.78)
168 143 80–84 44 26.2 33 23.1 1.13 (0.77–1.68)
76 117 85+ 36 47.7 48 41.0 1.15 (0.84–1.59)
2,539 1,619 all ages 262 10.3 168 10.4
5-year mortality 109 116 < 45 9 8.3 2 1.7 4.79 (1.06–21.7)
133 95 45–49 10 7.5 4 4.2 1.79 (0.58–5.52)
236 128 50–54 21 8.9 11 8.6 1.04 (0.52–2.08)
263 116 55–59 37 14.1 7 6.0 2.33 (1.07–5.07)
322 162 60–64 73 22.7 31 19.1 1.18 (0.81–1.72)
444 215 65–69 136 30.6 53 24.7 1.24 (0.95–1.63)
425 285 70–74 157 36.9 74 26.0 1.42 (1.12–1.79)
363 242 75–79 171 47.1 100 41.3 1.14 (0.95–1.37)
168 143 80–84 108 64.3 74 51.7 1.24 (1.02–1.51)
76 117 85+ 64 84.2 87 74.4 1.13.(0.98–1.31)
2,539 1,619 all ages 786 31.0 443 27.4
- Data about 6 patients (male <65 or women <50 and from 55 to 64 year) were not available as a consequence of privacy regulationBMC Cardiovascular Disorders 2009, 9:43 http://www.biomedcentral.com/1471-2261/9/43
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[14] have shown to influence the prognosis of PAD
patients. Unfortunately, no information in the registry
was available on these factors and therefore there cannot
be adjusted for these factors in the analysis of the data. On
the other hand, our primary goal was to provide absolute
mortality risks stratified by age and gender as absolute
risks are easier to interpret and they provide a clear pres-
entation of the size of the burden of disease in these
patients, which may be helpfull to increase awareness, as
it makes the problem as clear as possible.
Further aspects of our study that need critical considera-
tion are 1.) the study population is restricted to patients
with a first admission for PAD in the lower extremities.
Non-hospitalized patients were not included, while those
admitted for PAD in the lower extremities are most likely
more severe patients compared to those not admitted and
may therefore have a higher mortality risk as compared to
the entire group of patients with PAD in the lower extrem-
ities. 2.) In our data we found a higher percentage of
deaths after initial admission for PAD in the lower extrem-
ities due to lung cancer and respiratory diseases in men as
compared to women. This might be viewed as a higher
smoking prevalence among men. Smoking is one of the
major risk factors for the development of PAD in the
lower extremities [42-44], the prevalence is higher among
men [45] and smoking reduces survival in PAD patients
[46]. Smoking behaviour might affect our results through
overestimation of the gender differences in mortality risk.
However, exclusion of the deaths caused by lungcancer
and respiratory diseases did not change the gender differ-
ences in mortality risk (data not shown). 3.) The limita-
tion of previous admissions to maximal 6 years, might
have led to that some "first" patients with PAD in lower
extremities were actually recurrent patients with PAD in
the lower extremities. These may be more severe patients
and on the premise that severity is associated with a
higher mortality risk, possibly leading to some overesti-
mation of the mortality risk. The extent of which is diffi-
cult to quantify.
Table 4: Gender differences in short- and long-term mortality 
after a first hospital admission (1997 or 2000) for PAD in the 
lower extremities in the Netherlands
PAD in the lower extremities
HR (95% CI)*
Crude
28 days 0.67 (0.47–0.96)
1 year 0.90 (0.81–1.20)
5 years 1.15 (1.03–1.29)
Model I
28 days 0.85 (0.59–1.24)
1 year 1.17 (0.97–1.43)
5 years 1.36 (1.21–1.53)
Hazard ratio (95% Confidence interval) men vs women.
Model I: adjusted for age, co-morbidity (previous admissions for 
cardiovascular disease or diabetes mellitus)
Mortality risk at 5 years* after a first hospital admission for  PAD in the lower extremities, acute myocardial infarction  and ischemic stroke, by age Figure 1
Mortality risk at 5 years* after a first hospital admis-
sion for PAD in the lower extremities, acute myocar-
dial infarction and ischemic stroke, by age. Men * 
Mortality risks AMI, IS and GP extracted from other data 
[18,31,47] AMI: Acute myocardial Infarction, IS: Ischemic 
stroke, PAD: Peripheral arterial disease in the lower extrem-
ities, GP: General population
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Mortality risk at 5 years* after a first hospital admission for  PAD in the lower extremities, acute myocardial infarction  and ischemic stroke, by age Figure 2
Mortality risk at 5 years* after a first hospital admis-
sion for PAD in the lower extremities, acute myocar-
dial infarction and ischemic stroke, by age. Women * 
Mortality risks AMI, IS and GP extracted from other data 
[18,31,47] AMI: Acute myocardial Infarction, IS: Ischemic 
stroke, PAD: Peripheral arterial disease in the lower extrem-
ities, GP: General population
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Conclusion
Our study provides nationwide estimates of short- and
long-term risk of death after an initial hospital admission
for PAD in the lower extremities. Our findings demon-
strate that, 5-years mortality risk is high, especially in men
and comparable to that of patients admitted for acute
myocardial infarction or ischemic stroke. Though, in gen-
eral population the awareness of the severity of PAD in the
lower extremities is significantly lower than that for any
other cardiovascular disease and it seems that cardiovas-
cular risk factor management for prevention in PAD
patients is very modest.
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